Table 2.

Hazard ratio of each clinical event among study patients according to findings of electrocardiogram and ultrasonic echocardiography

	CVD				Non-fatal CVD				MACE
	Unadjusted		Adjusted		Unadjusted		Adjusted		Unadjusted		Adjusted
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Group A	Ref		Ref		Ref		Ref		Ref		Ref
ECG (−)
UCG (−)
Group B	1.880 (1.006–3.513)	0.048	1.621 (0.884–2.971)	0.118	1.894 (0.913–3.929)	0.086	1.551 (0.760–3.165)	0.228	1.744 (1.043–2.916)	0.034	1.520 (0.924–2.499)	0.099
ECG (+)
UCG (−)
Group C	3.095 (1.695–5.651)	< 0.001	2.963 (1.587–5.533)	< 0.001	3.747 (1.929–7.279)	< 0.001	3.196 (1.609–6.349)	< 0.001	2.338 (1.360–4.018)	0.002	2.320 (1.321–4.074)	0.003
ECG ( −)
UCG (+)
Group D	4.007 (2.434–6.598)	< 0.001	4.223 (2.426–7.351)	< 0.001	4.912 (2.820–8.553)	< 0.001	5.098 (2.772–9.376)	< 0.001	3.660 (2.345–5.713)	< 0.001	3.011 (1.838–4.933)	< 0.001
ECG (+)
UCG (+)

ECG electrocardiography, UCG ultrasonic echocardiography, CVD cardiovascular disease, MACE major adverse cardiovascular event